World journal of stem cells最新文献

{"title":"Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.","authors":"José Mauro Granjeiro, Priscila Grion de Miranda Borchio, Icaro Paschoal Brito Ribeiro, Katiucia Batista Silva Paiva","doi":"10.4252/wjsc.v16.i10.860","DOIUrl":"10.4252/wjsc.v16.i10.860","url":null,"abstract":"<p><p>The burgeoning field of bioengineering has witnessed significant strides due to the advent of stem cell models, particularly in their application in advanced therapy medicinal products (ATMPs). In this review, we examine the multifaceted impact of these developments, emphasizing the potential of stem cell models to enhance the sophistication of ATMPs and to offer alternatives to animal testing. Stem cell-derived tissues are particularly promising because they can reshape the preclinical landscape by providing more physiologically relevant and ethically sound platforms for drug screening and disease modelling. We also discuss the critical challenges of reproducibility and accuracy in measurements to ensure the integrity and utility of stem cell models in research and application. Moreover, this review highlights the imperative of stem cell models to align with regulatory standards, ensuring using stem cells in ATMPs translates into safe and effective clinical therapies. With regulatory approval serving as a gateway to clinical adoption, the collaborative efforts between scientists and regulators are vital for the progression of stem cell applications from bench to bedside. We advocate for a balanced approach that nurtures innovation within the framework of rigorous validation and regulatory compliance, ensuring that stem cell-base solutions are maximized to promote public trust and patient health in ATMPs.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 10","pages":"860-872"},"PeriodicalIF":3.6,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of the stromal vascular fraction and secretome in regenerative medicine.","authors":"Ratan Kumar Choudhary, Shanti Choudhary, Abhishek Tripathi","doi":"10.4252/wjsc.v16.i10.896","DOIUrl":"10.4252/wjsc.v16.i10.896","url":null,"abstract":"<p><p>Recently, we read a mini-review published by Jeyaraman <i>et al</i>. The article explored the optimal methods for isolating mesenchymal stromal cells from adipose tissue-derived stromal vascular fraction (SVF). Key factors include tissue source, processing techniques, cell viability assessment, and the advantages/disadvantages of autologous <i>vs</i> allogeneic use. The authors emphasized the need for standardized protocols for SVF isolation, ethical and regulatory standards for cell-based therapy, and safety to advance mesenchymal stromal cell-based therapies in human patients. This manuscript shares our perspective on SVF isolation in canines. We discussed future directions to potentiate effective regenerative medicine therapeutics in human and veterinary medicine.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 10","pages":"896-899"},"PeriodicalIF":3.6,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma-aminobutyric acid enhances miR-21-5p loading into adipose-derived stem cell extracellular vesicles to alleviate myocardial ischemia-reperfusion injury <i>via</i> TXNIP regulation.","authors":"Feng-Dan Wang, Yi Ding, Jian-Hong Zhou, En Zhou, Tian-Tian Zhang, Yu-Qi Fan, Qing He, Zong-Qi Zhang, Cheng-Yu Mao, Jun-Feng Zhang, Jing Zhou","doi":"10.4252/wjsc.v16.i10.873","DOIUrl":"10.4252/wjsc.v16.i10.873","url":null,"abstract":"<p><strong>Background: </strong>Myocardial ischemia-reperfusion injury (MIRI) poses a prevalent challenge in current reperfusion therapies, with an absence of efficacious interventions to address the underlying causes.</p><p><strong>Aim: </strong>To investigate whether the extracellular vesicles (EVs) secreted by adipose mesenchymal stem cells (ADSCs) derived from subcutaneous inguinal adipose tissue (IAT) under γ-aminobutyric acid (GABA) induction (GABA-EVs^IAT) demonstrate a more pronounced inhibitory effect on mitochondrial oxidative stress and elucidate the underlying mechanisms.</p><p><strong>Methods: </strong>We investigated the potential protective effects of EVs derived from mouse ADSCs pretreated with GABA. We assessed cardiomyocyte injury using terminal deoxynucleotidyl transferase dUTP nick end-labeling and Annexin V/propidium iodide assays. The integrity of cardiomyocyte mitochondria morphology was assessed using electron microscopy across various intervention backgrounds. To explore the functional RNA diversity between EVs^IAT and GABA-EVs^IAT, we employed microRNA (miR) sequencing. Through a dual-luciferase reporter assay, we confirmed the molecular mechanism by which EVs mediate thioredoxin-interacting protein (TXNIP). Western blotting and immunofluorescence were conducted to determine how TXNIP is involved in mediation of oxidative stress and mitochondrial dysfunction.</p><p><strong>Results: </strong>Our study demonstrates that, under the influence of GABA, ADSCs exhibit an increased capacity to encapsulate a higher abundance of miR-21-5p within EVs. Consequently, this leads to a more pronounced inhibitory effect on mitochondrial oxidative stress compared to EVs from ADSCs without GABA intervention, ultimately resulting in myocardial protection. On a molecular mechanism level, EVs regulate the expression of TXNIP and mitigating excessive oxidative stress in mitochondria during MIRI process to rescue cardiomyocytes.</p><p><strong>Conclusion: </strong>Administration of GABA leads to the specific loading of miR-21-5p into EVs by ADSCs, thereby regulating the expression of TXNIP. The EVs derived from ADSCs treated with GABA effectively ameliorates mitochondrial oxidative stress and mitigates cardiomyocytes damage in the pathological process of MIRI.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 10","pages":"873-895"},"PeriodicalIF":3.6,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?","authors":"Xiao-Qian Shan, Lan Zhao","doi":"10.4252/wjsc.v16.i10.854","DOIUrl":"10.4252/wjsc.v16.i10.854","url":null,"abstract":"<p><p>The intrinsic heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) and the intricate pathogenesis have impeded the advancement and clinical implementation of therapeutic interventions, underscoring the critical demand for novel treatments. A recent publication by Li <i>et al</i> proposes mesenchymal stem cells as promising effectors for the treatment of MASLD. This editorial is a continuum of the article published by Jiang <i>et al</i> which focuses on the significance of strategies to enhance the functionality of mesenchymal stem cells to improve efficacy in curing MASLD, including physical pretreatment, drug or chemical pretreatment, pretreatment with bioactive substances, and genetic engineering.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 10","pages":"854-859"},"PeriodicalIF":3.6,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell transplantation in cerebrovascular accidents: A global bibliometric analysis (2000-2023).","authors":"Jad El Masri, Ahmad Afyouni, Maya Ghazi, Karim Hamideh, Israe Moubayed, Abdo Jurjus, Hanine Haidar, Ruzanna Petrosyan, Pascale Salameh, Hassan Hosseini","doi":"10.4252/wjsc.v16.i9.832","DOIUrl":"10.4252/wjsc.v16.i9.832","url":null,"abstract":"<p><strong>Background: </strong>Cerebrovascular accident (CVA) is a major global contributor to death and disability. As part of its medical management, researchers have recognized the importance of promising neuroprotective strategies, where stem cell transplantation (SCT) is thought to confer advantages <i>via</i> trophic and neuroprotective effects.</p><p><strong>Aim: </strong>To evaluate the current state of research on SCT in patients with CVA, assess key trends and highlight literature gaps.</p><p><strong>Methods: </strong>PubMed was screened for SCT in CVA-related articles in October 2023, for each country during the period between 2000 and 2023. Using the World Bank data, total population and gross domestic product were collected for comparison. VOSviewer_1.6.19 was used to create the VOS figure using the results of the same query. Graphs and tables were obtained using Microsoft Office Excel.</p><p><strong>Results: </strong>A total of 6923 studies were identified on SCT in CVA, making 0.03% of all published studies worldwide. Approximately, 68% were conducted in high-income countries, with a significant focus on mesenchymal stem cells. The journal \"<i>Stroke</i>\" featured the largest share of these articles, with mesenchymal SCT having the highest rate of inclusion, followed by hematopoietic SCT. Over time, there has been a noticeable shift from <i>in vitro</i> studies, which assess stem cell proliferation and neurogenesis, to <i>in vivo</i> studies aimed at evaluating efficacy and safety. Additionally, the number of reviews increased along this approach.</p><p><strong>Conclusion: </strong>This bibliometric analysis provides a comprehensive guide for physicians and researchers in the field through an objective overview of research activity, and highlights both current trends and gaps. Having a potential therapeutic role in CVA, more research is needed in the future to focus on different aspects of SCT, aiming to reach a better treatment strategy and improve life quality in patients.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 9","pages":"832-841"},"PeriodicalIF":3.6,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions.","authors":"Yu-Xin Jin, Hang-Qi Hu, Jia-Cheng Zhang, Xi-Yan Xin, Yu-Tian Zhu, Yang Ye, Dong Li","doi":"10.4252/wjsc.v16.i9.842","DOIUrl":"10.4252/wjsc.v16.i9.842","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in liver cells and involves immune system activation, leading to histological changes, tissue damage, and clinical symptoms. A recent publication by Jiang <i>et al</i>, highlighted the potential of MSCs to mitigate in NAFLD progression by targeting various molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. In this editorial, we comment on their research and discuss the efficacy of MSC therapy in treating NAFLD.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 9","pages":"842-845"},"PeriodicalIF":3.6,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stem cells in wound healing: A bibliometric analysis as a powerful research tool.","authors":"Vera V Voinova, Daria V Vasina, Anton P Bonartsev","doi":"10.4252/wjsc.v16.i9.827","DOIUrl":"10.4252/wjsc.v16.i9.827","url":null,"abstract":"<p><p>Bibliographic analysis is still very rarely used in experimental basic study papers. The comprehensive bibliometric analysis of scientific literature on research progress and challenges in stem cell therapy for diabetic chronic wounds, which was conducted in the work of Shi <i>et al</i> can be a case study and a source of valuable information for writing reviews and experimental papers in this field. Basic experimental studies on a role of mesenchymal stem cells (MSCs) in wound healing that are published in 2023-2024, such as Zhang <i>et al</i> in 2023, Hu <i>et al</i> in 2023, Wang <i>et al</i> in 2023 are certainly also subjects for applying this powerful tool to analyze current research, challenges and perspectives in this field. This is due to the fact that these studies have addressed a great variety of aspects of the application of MSCs for the treatment of chronic wounds, such as using both the cells themselves and their various products: Sponges, hydrogels, exosomes, and genetic constructions. Such a wide variety of directions in the field of study and biomedical application of MSCs requires a deep understanding of the current state of research in this area, which can be provided by bibliometric analysis. Thus, the use of such elements of bibliographic analysis as publication count by year and analysis of top-10 keywords calculated independently or cited from bibliometric analysis studies can be safely recommended for every basic study manuscripts, primarily for the \"Introduction\" section, and review.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 9","pages":"827-831"},"PeriodicalIF":3.6,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative mesenchymal stem cell treatments for fatty liver disease.","authors":"Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng","doi":"10.4252/wjsc.v16.i9.846","DOIUrl":"10.4252/wjsc.v16.i9.846","url":null,"abstract":"<p><p>The incidence of non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) is increasing year by year due to changes in the contemporary environment and dietary structure, and is an important public health problem worldwide. There is an urgent need to continuously improve the understanding of their disease mechanisms and develop novel therapeutic strategies. Mesenchymal stem cells (MSCs) have shown promise as a potential therapeutic strategy in therapeutic studies of NAFLD and ALD. NAFLD and ALD have different triggers and their specific mechanisms of disease progression are different, but both involve disease processes such as hepatocellular steatosis and potential fibrosis, cirrhosis, and even hepatocellular carcinoma. MSCs have metabolic regulatory, anti-apoptotic, antioxidant, and immunomodulatory effects that together promote liver injury repair and functional recovery, and have demonstrated positive results in preclinical studies. This editorial is a continuum of Jiang <i>et al</i>'s review focusing on the advantages and limitations of MSCs and their derivatives as therapeutics for NAFLD and ALD. They detail how MSCs attenuate the progression of NAFLD by modulating molecular pathways involved in glucolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. Based on recent advances, we discuss MSCs and their derivatives as therapeutic strategies for NAFLD and ALD, providing useful information for their clinical application.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 9","pages":"846-853"},"PeriodicalIF":3.6,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment can alleviate programmed cell death in mesenchymal stem cells.","authors":"Xin-Xing Wan, Xi-Min Hu, Qi Zhang, Kun Xiong","doi":"10.4252/wjsc.v16.i8.773","DOIUrl":"10.4252/wjsc.v16.i8.773","url":null,"abstract":"<p><p>In this editorial, we delved into the article titled \"Cellular preconditioning and mesenchymal stem cell ferroptosis.\" This groundbreaking study underscores a pivotal discovery: Ferroptosis, a type of programmed cell death, drastically reduces the viability of donor mesenchymal stem cells (MSCs) after engraftment, thereby undermining the therapeutic value of cell-based therapies. Furthermore, the article proposes that by manipulating ferroptosis mechanisms through preconditioning, we can potentially enhance the survival rate and functionality of MSCs, ultimately amplifying their therapeutic potential. Given the crucial role ferroptosis plays in shaping the therapeutic outcomes of MSCs, we deem it imperative to further investigate the intricate interplay between programmed cell death and the therapeutic effectiveness of MSCs.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 8","pages":"773-779"},"PeriodicalIF":3.6,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor.","authors":"Qi-Hong Chen, Ying Zhang, Xue Gu, Peng-Lei Yang, Jun Yuan, Li-Na Yu, Jian-Mei Chen","doi":"10.4252/wjsc.v16.i8.811","DOIUrl":"10.4252/wjsc.v16.i8.811","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary fibrosis is one of the main reasons for the high mortality rate among acute respiratory distress syndrome (ARDS) patients. Mesenchymal stromal cell-derived microvesicles (MSC-MVs) have been shown to exert antifibrotic effects in lung diseases.</p><p><strong>Aim: </strong>To investigate the effects and mechanisms of MSC-MVs on pulmonary fibrosis in ARDS mouse models.</p><p><strong>Methods: </strong>MSC-MVs with low hepatocyte growth factor (HGF) expression (siHGF-MSC-MVs) were obtained <i>via</i> lentivirus transfection and used to establish the ARDS pulmonary fibrosis mouse model. Following intubation, respiratory mechanics-related indicators were measured <i>via</i> an experimental small animal lung function tester. Homing of MSC-MVs in lung tissues was investigated by near-infrared live imaging. Immunohistochemical, western blotting, ELISA and other methods were used to detect expression of pulmonary fibrosis-related proteins and to compare effects on pulmonary fibrosis and fibrosis-related indicators.</p><p><strong>Results: </strong>The MSC-MVs gradually migrated and homed to damaged lung tissues in the ARDS model mice. Treatment with MSC-MVs significantly reduced lung injury and pulmonary fibrosis scores. However, low expression of HGF (siHGF-MSC-MVs) significantly inhibited the effects of MSC-MVs (<i>P</i> < 0.05). Compared with the ARDS pulmonary fibrosis group, the MSC-MVs group exhibited suppressed expression of type I collagen antigen, type III collagen antigen, and the proteins transforming growth factor-β and α-smooth muscle actin, whereas the siHGF-MVs group exhibited significantly increased expression of these proteins. In addition, pulmonary compliance and the pressure of oxygen/oxygen inhalation ratio were significantly lower in the MSC-MVs group, and the effects of the MSC-MVs were significantly inhibited by low HGF expression (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>MSC-MVs improved lung ventilation functions and inhibited pulmonary fibrosis in ARDS mice partly <i>via HGF</i> mRNA transfer.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"16 8","pages":"811-823"},"PeriodicalIF":3.6,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}